Researchers may have discovered new drugs that could save the lives of patients with new coronary diseases.

According tomedia reports, there are several factors that make the new crown epidemic so scary: the virus is easy to spread, it can infect anyone, regardless of gender, age and place; the virus is as powerful in winter and summer; the incubation period can be as long as two weeks, before symptoms appear, the person may be contagious; some people may not even have symptoms at all, but still spread the disease; and some new coronary pneumonia patients can quickly deteriorate, with attendant complications that can lead to death.

Researchers may have discovered new drugs that could save the lives of patients with new coronary diseases.


While we now have ways to mitigate all these factors and overcome the epidemic, the world is far from winning. Current hygiene and safety measures include keeping social distance, wearing masks, and washing hands often. In addition, adequate testing activity and contact tracing can help health officials identify and isolate those infected who may not even realize they are infected with the virus. But there is still a lack of treatment to deal with the most disturbing aspect of the disease, the risk of death. But in recent days, researchers have brought good news in this regard, as researchers now believe they have found a class of drugs that could significantly reduce the mortality rate in patients with severe neo-coronary pneumonia. These drugs won’t save all people severely infected with new coronary pneumonia, but they could be a breakthrough and ultimately save many lives.

In mid-June, British researchers published the findings of a local study of dexamisson, a drug that has been said to save the lives of patients with severe neocephal pneumonia. However, dexamisson can only be effective under certain conditions, not for everyone. This conclusion is still true today, but now there is a huge update on this issue, because other drugs that look like they come from the same category can get similar benefits. Not only that, but the use of corticosteroids can significantly reduce mortality by up to 20%.

The new findings come from an analysis of seven international trials, Reuters reported. This progress is important and WHO will update its recommendations for the treatment of new coronary pneumonia. According to the report, the analysis analyzed experiments on low-dose hydrogenated pines, dexamissons and methyl-strength pines. Researchers say steroids can improve survival rates for new coronary pneumonia patients who need intensive care after being admitted to the hospital.

“This is equivalent to about 68 percent of patients with neocodone (the most serious neocooproid pneumonia) who survive after treatment with corticosteroids, compared with about 60 percent without glucoticoids,” the researchers said in a statement. “

Jonathan Sterne, professor of medical statistics and epidemiology at the University of Bristol in the UK, said in a press release: “Steroids are a cheap and easily available drug and our analysis has shown that they are effective in reducing the number of deaths among those most affected by neo-corona pneumonia. “

Sterne and his colleagues looked at data from the United Kingdom, Brazil, Canada, China, France, Spain and the United States and found that the drugs were effective in the most severely ill patients and had nothing to do with age, gender or duration. It is also important to conclude that this treatment is effective regardless of whether the patient is using breathing at the beginning of steroid treatment.

Martin Landray, of the University of Oxford, told reporters: “These results are very clear and can be applied immediately to clinical practice. Low-dose corticosteroids in critically ill patients with new coronary pneumonia… The risk of death can be significantly reduced. Landray is understood to have been involved in Thessemisson’s research.

It is worth noting, however, that steroids do not prevent or cure all patients with new coronary pneumonia. Professor Anthony Gordon, of Imperial College London, who was involved in the study, said: “While these results are impressive, they do not cure the disease. We now have something useful, but there is no cure, so it is important to maintain all prevention strategies. “

It is also important to note that steroids do not prevent infection.